- Home
- WEA vs VTYX Comparison
WEA vs VTYX Comparison
Compare WEA & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- VTYX
- Stock Information
- Founded
- WEA 2002
- VTYX 2018
- Country
- WEA United States
- VTYX United States
- Employees
- WEA N/A
- VTYX N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- WEA Finance
- VTYX Health Care
- Exchange
- WEA Nasdaq
- VTYX Nasdaq
- Market Cap
- WEA 129.9M
- VTYX 154.9M
- IPO Year
- WEA N/A
- VTYX 2021
- Fundamental
- Price
- WEA $11.16
- VTYX $2.38
- Analyst Decision
- WEA
- VTYX Buy
- Analyst Count
- WEA 0
- VTYX 2
- Target Price
- WEA N/A
- VTYX $9.00
- AVG Volume (30 Days)
- WEA 46.1K
- VTYX 499.4K
- Earning Date
- WEA 01-01-0001
- VTYX 11-06-2025
- Dividend Yield
- WEA 7.87%
- VTYX N/A
- EPS Growth
- WEA N/A
- VTYX N/A
- EPS
- WEA N/A
- VTYX N/A
- Revenue
- WEA N/A
- VTYX N/A
- Revenue This Year
- WEA N/A
- VTYX N/A
- Revenue Next Year
- WEA N/A
- VTYX N/A
- P/E Ratio
- WEA N/A
- VTYX N/A
- Revenue Growth
- WEA N/A
- VTYX N/A
- 52 Week Low
- WEA $9.60
- VTYX $0.78
- 52 Week High
- WEA $11.29
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- WEA 71.78
- VTYX 42.21
- Support Level
- WEA $10.89
- VTYX $2.31
- Resistance Level
- WEA $11.03
- VTYX $2.67
- Average True Range (ATR)
- WEA 0.08
- VTYX 0.16
- MACD
- WEA 0.01
- VTYX -0.02
- Stochastic Oscillator
- WEA 94.74
- VTYX 14.00
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.